SecSonar.com

SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

SAB Biotherapeutics, Inc. (SABS) is a Biotechnology company based in US with a market capitalization of $34.6M. Free cash flow was negative at -$45.7M. This page tracks SABS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 63 employees · IPO Feb 9, 2021

Valuation

Valuation & price

$3.70 · as of May 17, 2026 · -19.4% vs 52w high

17.1

P/E ratio

Latest-FY diluted EPS

0.23

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.59$3.23$1.88Jul 25Dec 25Jul 26Jul 7, 25$1.96Jul 9, 25$2.55Jul 11, 25$2.60Jul 15, 25$2.54Jul 17, 25$2.84Jul 21, 25$2.70Jul 23, 25$2.49Jul 25, 25$2.55Jul 29, 25$2.27Jul 31, 25$1.88Aug 4, 25$2.28Aug 6, 25$2.19Aug 11, 25$2.02Aug 13, 25$2.15Aug 15, 25$2.22Aug 19, 25$2.00Aug 21, 25$2.06Aug 25, 25$2.22Aug 27, 25$2.12Aug 29, 25$2.08Sep 3, 25$2.32Sep 5, 25$2.27Sep 9, 25$2.13Sep 11, 25$2.12Sep 16, 25$2.15Sep 18, 25$2.79Sep 22, 25$2.48Sep 24, 25$2.16Sep 26, 25$2.01Sep 30, 25$2.01Oct 2, 25$2.01Oct 6, 25$2.29Oct 8, 25$2.34Oct 10, 25$2.29Oct 14, 25$2.30Oct 16, 25$2.17Oct 21, 25$3.00Oct 23, 25$2.92Oct 27, 25$3.03Oct 29, 25$3.04Oct 31, 25$3.25Nov 4, 25$3.25Nov 6, 25$3.10Nov 10, 25$3.20Nov 12, 25$3.41Nov 14, 25$3.24Nov 18, 25$3.91Nov 20, 25$3.80Nov 25, 25$3.93Nov 28, 25$3.95Dec 2, 25$3.64Dec 4, 25$3.80Dec 8, 25$3.55Dec 10, 25$3.71Dec 12, 25$3.81Dec 16, 25$3.99Dec 18, 25$3.95Dec 22, 25$3.84Dec 24, 25$3.84Dec 29, 25$3.65Jan 2, 26$3.77Jan 6, 26$3.62Jan 8, 26$3.86Jan 12, 26$3.74Jan 14, 26$4.00Jan 16, 26$3.98Jan 21, 26$4.03Jan 23, 26$4.04Jan 27, 26$4.28Jan 29, 26$4.42Feb 2, 26$4.38Feb 4, 26$4.23Feb 9, 26$4.23Feb 11, 26$4.18Feb 13, 26$3.85Feb 18, 26$3.74Feb 20, 26$3.57Feb 24, 26$3.74Feb 26, 26$4.13Mar 2, 26$4.07Mar 4, 26$3.93Mar 6, 26$3.79Mar 10, 26$4.10Mar 12, 26$4.59Mar 17, 26$4.07Mar 19, 26$3.78Mar 23, 26$3.93Mar 25, 26$3.82Mar 27, 26$3.85Mar 31, 26$3.83Apr 2, 26$3.88Apr 7, 26$3.76Apr 9, 26$3.83Apr 13, 26$3.90Apr 15, 26$4.05Apr 17, 26$3.85Apr 22, 26$3.99Apr 24, 26$3.52Apr 28, 26$3.53Apr 30, 26$3.74May 4, 26$3.69May 6, 26$3.80May 8, 26$4.11May 12, 26$3.62May 14, 26$3.89May 18, 26$3.56May 20, 26$3.68May 22, 26$3.90May 28, 26$3.57Jun 1, 26$3.44Jun 3, 26$3.36Jun 5, 26$3.38Jun 9, 26$3.36Jun 11, 26$3.38Jun 15, 26$3.90Jun 17, 26$3.86Jun 22, 26$3.93Jun 24, 26$3.84Jun 26, 26$3.80Jul 2, 26$3.92
$1.8852-week range$4.59
Loading valuation history…

Fundamentals

Key fundamentals

$34.6M

Market cap

—

Revenue growth (YoY)

-262.4%

Gross margin

-$45.7M

Free cash flow (USD)

-$90.6M

Net debt

Net cash position

108.5%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$3.4MFY 2020$55.2MFY 2021$60.9MFY 2022$23.9MFY 2023$2.2MFY 2024$1.3MFY 2025$0.00
$3.4M$0

Free cash flow by year

2019 → 2025

FY 2019$-9.8MFY 2020$-2.7MFY 2021$-9.0MFY 2022$-25.6MFY 2023$-25.3MFY 2024$-34.6MFY 2025$-45.7M
-$9.8M-$45.7M

Gross margin by year

2021 → 2024

FY 202197.3%FY 202286.2%FY 2023-67.3%FY 2024-262.4%
97.3%-262.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 18, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • 8-K eventManufacturing Agreement SignedMay 4, 2026Filing
  • 8-K eventClinical Trial Data PresentationApr 22, 2026Filing

Questions

Frequently asked questions

What is SAB Biotherapeutics, Inc.'s market cap?

SAB Biotherapeutics, Inc. (SABS) has a market capitalization of $34.6M.

What is SABS's P/E ratio?

SABS trades at a price-to-earnings ratio of 17.1, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is SABS's price-to-book (P/B) ratio?

SABS trades at 0.23 times book value per share.

Are insiders buying SABS stock?

SEC Form 4 filings show no open-market insider buys at SAB Biotherapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

RNXT

RenovoRx, Inc.

$35M

ALGS

Aligos Therapeutics, Inc.

$35.5M

INMB

INmune Bio, Inc.

$36.3M

ATHE

Alterity Therapeutics Limited

$36.5M

BTAI

BioXcel Therapeutics, Inc.

$37.1M

VERU

Veru Inc.

$37.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.